메뉴 건너뛰기




Volumn 6, Issue , 2008, Pages

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

EID: 48949116261     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-6-12     Document Type: Article
Times cited : (39)

References (33)
  • 1
    • 33749440615 scopus 로고    scopus 로고
    • A very effective treatment for neovascular macular degeneration
    • 10.1056/NEJMe068191 17021326
    • Stone EM A very effective treatment for neovascular macular degeneration N Engl J Med 2006, 355:1493-1495. 10.1056/NEJMe068191 17021326
    • (2006) N Engl J Med , vol.355 , pp. 1493-1495
    • Stone, E.M.1
  • 4
    • 33749426139 scopus 로고    scopus 로고
    • The price of sight - Ranibizumab, bevacizumab, and the treatment of macular degeneration
    • 10.1056/NEJMp068185 17021315
    • Steinbrook R The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration N Engl J Med 2006, 355:1409-1412. 10.1056/NEJMp068185 17021315
    • (2006) N Engl J Med , vol.355 , pp. 1409-1412
    • Steinbrook, R.1
  • 6
    • 33947403618 scopus 로고    scopus 로고
    • An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration
    • 10.1016/j.ajo.2007.01.028 17386270
    • Fung AE Lalwani GA Rosenfeld PJ Dubovy SR Michels S Feuer WJ Puliafito CA Davis JL Flynn J Esquiabro M An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration Am J Ophthalmol 2007, 143:566-583. 10.1016/j.ajo.2007.01.028 17386270
    • (2007) Am J Ophthalmol , vol.143 , pp. 566-583
    • Fung, A.E.1    Lalwani, G.A.2    Rosenfeld, P.J.3    Dubovy, S.R.4    Michels, S.5    Feuer, W.J.6    Puliafito, C.A.7    Davis, J.L.8    Flynn, J.9    Esquiabro, M.10
  • 7
    • 33847226702 scopus 로고    scopus 로고
    • Williamstown, MA, TreeAge Software Inc
    • TreeAge Pro 2006 User's Manual Williamstown, MA, TreeAge Software Inc; 2006.
    • (2006) TreeAge Pro 2006 User's Manual
  • 8
    • 33644880264 scopus 로고    scopus 로고
    • Changing from Snellen to LogMAR: Debate or delay?
    • 10.1111/j.1442-9071.2006.01135.x 16451251
    • Hussain B Saleh GM Sivaprasad S Hammond CJ Changing from Snellen to LogMAR: Debate or delay? Clin Experiment Ophthalmol 2006, 34:6-8. 10.1111/j.1442-9071.2006.01135.x 16451251
    • (2006) Clin Experiment Ophthalmol , vol.34 , pp. 6-8
    • Hussain, B.1    Saleh, G.M.2    Sivaprasad, S.3    Hammond, C.J.4
  • 10
    • 0142244325 scopus 로고    scopus 로고
    • Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: A systematic review and economic evaluation
    • 12709292
    • Meads C Salas C Roberts T Moore D Fry-Smith A Hyde C Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: A systematic review and economic evaluation Health Technol Assess 2003, 7:v-98. 12709292
    • (2003) Health Technol Assess , vol.7
    • Meads, C.1    Salas, C.2    Roberts, T.3    Moore, D.4    Fry-Smith, A.5    Hyde, C.6
  • 11
    • 0842267227 scopus 로고    scopus 로고
    • Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration
    • 10.1016/j.ophtha.2003.05.030 15019371
    • Olsen TW Feng X Kasper TJ Rath PP Steuer ER Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration, Ophthalmology 2004, 111:250-255. 10.1016/j.ophtha.2003.05.030 15019371
    • (2004) Ophthalmology , vol.111 , pp. 250-255
    • Olsen, T.W.1    Feng, X.2    Kasper, T.J.3    Rath, P.P.4    Steuer, E.R.5
  • 12
    • 33749440219 scopus 로고    scopus 로고
    • Mechanisms of disease: Age-related macular degeneration
    • 10.1056/NEJMra062326 17021323
    • de Jong PTVM Mechanisms of disease: Age-related macular degeneration N Engl J Med 2006, 355:1474-1485. 10.1056/NEJMra062326 17021323
    • (2006) N Engl J Med , vol.355 , pp. 1474-1485
    • de Jong, P.T.V.M.1
  • 14
    • 0033499369 scopus 로고    scopus 로고
    • Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration
    • 10.1016/S0161-6420(99)90340-8 10485549
    • Sunness JS Gonzalez-Baron J Applegate CA Bressler NM Tian Y Hawkins B Barron Y Bergman A Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration Ophthalmology 1999, 106:1768-1779. 10.1016/S0161-6420(99)90340-8 10485549
    • (1999) Ophthalmology , vol.106 , pp. 1768-1779
    • Sunness, J.S.1    Gonzalez-Baron, J.2    Applegate, C.A.3    Bressler, N.M.4    Tian, Y.5    Hawkins, B.6    Barron, Y.7    Bergman, A.8
  • 16
    • 33846494063 scopus 로고    scopus 로고
    • Association between vision loss and higher medical care costs in Medicare beneficiaries: Costs are greater for those with progressive vision loss
    • 10.1016/j.ophtha.2006.07.054 17270673
    • Javitt JC Zhou Z Willke RJ Association between vision loss and higher medical care costs in Medicare beneficiaries: Costs are greater for those with progressive vision loss Ophthalmology 2007, 114:238-245. 10.1016/j.ophtha.2006.07.054 17270673
    • (2007) Ophthalmology , vol.114 , pp. 238-245
    • Javitt, J.C.1    Zhou, Z.2    Willke, R.J.3
  • 17
    • 33845735049 scopus 로고    scopus 로고
    • Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration
    • 10.1097/01.iae.0000254890.48272.5a 17151494
    • Schmier JK Halpern MT Covert D Delgado J Sharma S Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration Retina 2006, 26:1056-1062. 10.1097/ 01.iae.0000254890.48272.5a 17151494
    • (2006) Retina , vol.26 , pp. 1056-1062
    • Schmier, J.K.1    Halpern, M.T.2    Covert, D.3    Delgado, J.4    Sharma, S.5
  • 18
    • 0033986170 scopus 로고    scopus 로고
    • Utility values and age-related macular degeneration
    • 10636413
    • Brown GC Sharma S Brown MM Kistler J Utility values and age-related macular degeneration Arch Ophthalmol 2000, 118:47-51. 10636413
    • (2000) Arch Ophthalmol , vol.118 , pp. 47-51
    • Brown, G.C.1    Sharma, S.2    Brown, M.M.3    Kistler, J.4
  • 19
    • 0036596664 scopus 로고    scopus 로고
    • Are we blind to injuries in the visually impaired? A review of the literature
    • Inj Prev British Medical Association 1730864 12120837 10.1136/ip.8.2.155
    • Legood R Scuffham P Cryer C Are we blind to injuries in the visually impaired? A review of the literature. Inj Prev British Medical Association 2002, 8:155-160. 1730864 12120837 10.1136/ip.8.2.155
    • (2002) Inj Prev , vol.8 , pp. 155-160
    • Legood, R.1    Scuffham, P.2    Cryer, C.3
  • 20
    • 0032778397 scopus 로고    scopus 로고
    • Acute care hospital utilization by patients with visual impairment
    • 10408461
    • Morse AR Yatzkan E Berberich B Arons RR Acute care hospital utilization by patients with visual impairment Arch Ophthalmol 1999, 117:943-949. 10408461
    • (1999) Arch Ophthalmol , vol.117 , pp. 943-949
    • Morse, A.R.1    Yatzkan, E.2    Berberich, B.3    Arons, R.R.4
  • 22
    • 0003469046 scopus 로고    scopus 로고
    • New York, Oxford University Press Gold MR, Siegel JE, Russell LB and Weinstein MC
    • Cost-effectiveness in health and medicine New York, Oxford University Press Gold MR, Siegel JE, Russell LB and Weinstein MC 1996.
    • (1996) Cost-effectiveness in Health and Medicine
  • 23
    • 28144444941 scopus 로고    scopus 로고
    • Quality, innovation, and value for money. NICE and the British National Health Service
    • 10.1001/jama.294.20.2618 16304076
    • Pearson SD Rawlins MD Quality, innovation, and value for money. NICE and the British National Health Service JAMA 2005, 294:2618-2622. 10.1001/ jama.294.20.2618 16304076
    • (2005) JAMA , vol.294 , pp. 2618-2622
    • Pearson, S.D.1    Rawlins, M.D.2
  • 24
    • 0037334224 scopus 로고    scopus 로고
    • Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk
    • The Lancet Publishing Group, a division of Elsevier Science Ltd. 9359 10.1016/S0140-6736(03)12655-4
    • Murray CJL Lauer JA Hutubessy RCW Niessen L Tomijima N Rodgers A Lawes CMM Evans DB Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. The Lancet The Lancet Publishing Group, a division of Elsevier Science Ltd. 2003, 361:9359 717-725 10.1016/S0140-6736(03)12655-4
    • (2003) The Lancet , vol.361 , pp. 717-725
    • Murray, C.J.L.1    Lauer, J.A.2    Hutubessy, R.C.W.3    Niessen, L.4    Tomijima, N.5    Rodgers, A.6    Lawes, C.M.M.7    Evans, D.B.8
  • 25
    • 33750094121 scopus 로고    scopus 로고
    • Calculating QALYs, comparing QALY and DALY calculations
    • 10.1093/heapol/czl018 16877455
    • Sassi F Calculating QALYs, comparing QALY and DALY calculations Health Policy Plan 2006, 21:402-408. 10.1093/heapol/czl018 16877455
    • (2006) Health Policy Plan , vol.21 , pp. 402-408
    • Sassi, F.1
  • 26
    • 0003845462 scopus 로고    scopus 로고
    • The World Factbook 2007 https://www.cia.gov/cia/publications/factbook/ geos/us.html;
    • (2007) The World Factbook
  • 27
    • 34447281815 scopus 로고    scopus 로고
    • Relevance of Cost-Effectiveness Analysis to Clinicians and Policy Makers
    • 10.1001/jama.298.2.221 17622605
    • Detsky AS Laupacis A Relevance of Cost-Effectiveness Analysis to Clinicians and Policy Makers JAMA 2007, 298:221-224. 10.1001/ jama.298.2.221 17622605
    • (2007) JAMA , vol.298 , pp. 221-224
    • Detsky, A.S.1    Laupacis, A.2
  • 28
    • 34548324016 scopus 로고    scopus 로고
    • Ranibizumab (Lucentis) versus bevacizumab (Avastin): Modelling cost effectiveness
    • 10.1136/bjo.2007.116616 17431015
    • Raftery J Clegg A Jones J Tan SC Lotery A Ranibizumab (Lucentis) versus bevacizumab (Avastin): Modelling cost effectiveness Br J Ophthalmol 2007, 91:1244-1246. 10.1136/bjo.2007.116616 17431015
    • (2007) Br J Ophthalmol , vol.91 , pp. 1244-1246
    • Raftery, J.1    Clegg, A.2    Jones, J.3    Tan, S.C.4    Lotery, A.5
  • 31
    • 33846973644 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • [letter] 17310523
    • Gillies MC Wong TY Ranibizumab for neovascular age-related macular degeneration [letter] N Engl J Med 2007, 356:748-750. 17310523
    • (2007) N Engl J Med , vol.356 , pp. 748-750
    • Gillies, M.C.1    Wong, T.Y.2
  • 32
    • 33847006246 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • [authors' reply]
    • Rosenfeld PJ Brown DM Schneider S Ranibizumab for neovascular age-related macular degeneration [authors' reply] N Engl J Med 2007, 356:749-750.
    • (2007) N Engl J Med , vol.356 , pp. 749-750
    • Rosenfeld, P.J.1    Brown, D.M.2    Schneider, S.3
  • 33
    • 48949110517 scopus 로고    scopus 로고
    • Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation
    • Colquitt JL Jones J Tan SC Takeda A Clegg AJ Price A Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation Southampton Health Technology Assessments Centre 2007. http://www.nice.org.uk/nicemedia/pdf/ PegaptanibRanbizumabAssessmentReport.pdf
    • (2007) Southampton Health Technology Assessments Centre
    • Colquitt, J.L.1    Jones, J.2    Tan, S.C.3    Takeda, A.4    Clegg, A.J.5    Price, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.